- List articles in this issue
Progressive Muscle Relaxation Therapy for Atopic Dermatitis: Objective Assessment of Efficacy
The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL-13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait
anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = –0.475, p = 0.019; trait anxiety: R = –0.418, p = 0.042) and pruritus scores (R = –0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline.
Byung Gi Bae, Sang Ho Oh, Chang Ook Park, Seongmin Noh, Ji Yeon Noh, Kyung Ran Kim, Kwang Hoon Lee
Alexander F. Psychological aspects of medicine. Psychosom Med 1939; 1: 7.
Huovinen E, Kaprio J, Koskenvuo M. Asthma in relation to personality traits, life satisfaction, and stress: a prospective study among 11,000 adults. Allergy 2001; 56: 971–977.
Kodama A, Horikawa T, Suzuki T, Ajiki W, Takashima T, Harada S, et al. Effect of stress on atopic dermatitis: investigation in patients after the great Hanshin earthquake. J Allergy Clin Immunol 1999; 104: 173–176.
Hashizume H, Takigawa M. Anxiety in allergy and atopic dermatitis. Curr Opin Allergy Clin Immunol 2006; 6: 335–339.
Arck P, Paus R. From the brain-skin connection: the neuroendocrine-immune misalliance of stress and itch. Neuroimmunomodulation 2006; 13: 347–356.
Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the ‘brain-skin connection’. Trends Immunol 2006; 27: 32–39.
Oh SH, Bae BG, Park CO, Noh JY, Park IH, Wu WH, et al. Association of stress with symptoms of atopic dermatitis. Acta Derm Venereol 2010; 90: 582–588.
Chida Y, Steptoe A, Hirakawa N, Sudo N, Kubo C. The effects of psychological intervention on atopic dermatitis – a systematic review and meta-analysis. Int Arch Allergy Immunol 2007; 144: 1–9.
Vickers A, Zollman C. ABC of complementary medicine. Hypnosis and relaxation therapies. BMJ 1999; 20: 1346–1349.
Ersser SJ, Latter S, Sibley A, Satherley PA, Welbourne S. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2007: CD004054.
Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; suppl. 92: 44–47.
Jacobson E. Electrical measurement concerning muscular contraction (tonus) and the cultivation of relaxation in man-relaxation-time of individuals. Am J Physiol 1934; 108: 573.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.
Hahn HM, Yum TH, Shin YW, Kim KH, Yoon DJ, Chung KJ. A standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc 1986; 25: 487–500.
Spielberger C, Gorsuch R, Edward L. STAI manual for the State-Trait Anxiety Inventory (“self-evaluation questionnaire”). Palo Alto, CA: Consulting Psychologists Press; 1970.
Hahn DW, Lee CH, Chon KK. Korean adaptation of Spielberger’s STAI (K-STAI). Korean J Health Psychol 1996; 1: 1–14.
Leary MR, Kowalski RM. The Interaction Anxiousness Scale: construct and criterion-related validity. J Pers Assess 1993; 61: 136–146.
Miller L, Murphy R, Buss A. Consciousness of body: private and public. J Pers Soc Psychol 1981; 41: 397–406.
Tofte S, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin J. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11: S197.
Arndt J, Smith N, Tausk F. Stress and atopic dermatitis. Curr Allergy Asthma Rep 2008; 8: 312–317.
Linnet J, Jemec GB. Anxiety level and severity of skin condition predicts outcome of psychotherapy in atopic dermatitis patients. Int J Dermatol 2001; 40: 632–636.
Biro T, Ko M, Bromm B, Wei E, Bigliardi P, Siebenhaar F, et al. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 2005; 14: 225.
Conrad A, Roth W. Muscle relaxation therapy for anxiety disorders: it works but how? J Anxiety Disord 2007; 21: 243–264.
Gaylord C, Orme-Johnson D, Travis F. The effects of the transcendental technique and progressive muscle relaxation on EEG coherence, stress reactivity, and mental health in black adults. Int J Neurosci 1989; 46: 77–86.
Alleva E, Petruzzi S, Cirulli F, Aloe L. NGF regulatory role in stress and coping of rodents and humans. Pharmacol Biochem Behav 1996; 54: 65–72.
Botchkarev VA, Yaar M, Peters EM, Raychaudhuri SP, Botchkareva NV, Marconi A, et al. Neurotrophins in skin biology and pathology. J Invest Dermatol 2006; 126: 1719–1727.
Karlsson R, Choe J, Cameron H, Thorsell A, Crawley J, Holmes A, et al. The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology 2008; 195: 547–557.
Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 1999; 10: 3003–3007.
Bannon AW, Seda J, Carmouche M, Francis JM, Norman MH, Karbon B, et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 2000; 868: 79–87.
Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry 2000; 47: 526–539.
Wallengren J. Vasoactive peptides in the skin. J Invest Dermatol Symp Proc 1997; 2: 49–55.
Steinhoff M, Stander S, Seeliger S, Ansel J, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139: 1479.
Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002; 147: 71–79.
Sin A, Roche E, Togias A, Lichtenstein L, Schroeder J. Nerve growth factor or IL-3 induces more IL-13 production from basophils of allergic subjects than from basophils of nonallergic subjects. J Allergy Clin Immunol 2001; 108: 387–393.
Zhou Z, Zhu G, Hariri A, Enoch M, Scott D, Sinha R, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008; 452: 997–1001.
There are no related articles.
Share with your friends
There is no supplementary for this article.
Volume 92, Issue 1
View at PubMed